DMAC
DiaMedica Therapeutics Inc
7.90$
+1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -293.2% | -3,236.8% | -3,112.9% | -755.4% | – | – | – | – | – | – | – | – | – | – | -1,139.2% | – | – | – | – | – | – | – | |
| 18.9% | 109.6% | 12.9% | 11.4% | – | – | – | – | – | – | – | – | – | – | 3.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 124.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 131.8% | – | – | – | – | – | – | – | |
| 1,476.6% | -2,551.3% | -102.8% | 89.0% | – | – | – | – | – | – | – | – | – | – | -127.2% | – | – | – | – | – | – | – | |
| 305.4% | 299.8% | 423.1% | 184.4% | – | – | – | – | – | – | – | – | – | – | 10.0% | – | – | – | – | – | – | – | |
| -305.4% | -299.8% | -423.1% | -184.4% | – | – | – | – | – | – | – | – | – | – | -10.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4,243.2% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.0% | – | – | – | – | – | – | – | |
| 470.8% | 4,575.8% | 3,519.8% | 2,922.2% | – | – | – | – | – | – | – | – | – | – | 4,243.2% | – | – | – | – | – | – | – | |
| -127.8% | 1,039.2% | -16.2% | 1,982.4% | – | – | – | – | – | – | – | – | – | – | 3,094.0% | – | – | – | – | – | – | – | |
| -598.6% | -3,536.6% | -3,536.0% | -939.8% | – | – | – | – | – | – | – | – | – | – | -1,149.2% | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.